BioNTech price target lowered to $130 from $145 at Citi
Citi lowered the firm’s price target on BioNTech (BNTX) to $130 from $145 and keeps a Buy rating on the shares. The departures of the company’s co-founders is a surprise but the share selloff offers a good entry point, the analyst tells investors in a research note. Citi says BioNTech’s pipeline has multiple Phase 3 opportunities.
Read More on BNTX:
- Balancing Near-Term Headwinds and Strategic Transition: Why a Hold Rating Remains Warranted
- BioNTech: Attractive Near-Cash Valuation with Robust Late-Stage Pipeline Offsetting Revenue Declines and Leadership Transition Risks
- Jefferies cuts BioNTech price target, says stock is cheap
- Clear Street lowers BioNTech price target, says buy on weakness
- BioNTech falls -19.9%
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
NASDAQ TRADE HALT CONTINUES <UCFIW.O> REASON NOT AVAILABLE AT 01:18 PM
Lundin Gold hits record 1035g in Ecuador
NASDAQ TRADE HALT <QH.O> VOLATILITY TRADING PAUSE AT 01:12 PM
Bitwise Buys XRP for Three Consecutive Days
Crypto prices
More
